Under the terms of the agreement, Merck’s division Merck Serono US evaluate the novel experimental combinations of agents that could block specific pathways in cancer cells.
The novel combinations involve Merck Serono‘s MEK inhibitor MSC1936369B (also known as AS703026), Sanofi-aventis PI3K/mTOR inhibitor SAR245409 (also known as XL765) and class I PI3K inhibitor SAR245408 (also known as XL147), respectively.
Speaking of the agreement, the Global Oncology Head and Vice President of Sanofi Aventis, Debasish Roychowdhury said that this collaboration reinforces their commitment to maximize their portfolio and to provide better treatments for patients with cancer.
Are you looking for a new role in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs online.